Entrada Therapeutics, Inc. (TRDA) SEC filings

TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30

$5.17−0.27 (-4.96%)

Close on Nov 12, 2026Market cap $201.30MP/E –Yield –

SEC filings

40 of Entrada Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Oct 14, 2026	Oct 14, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Aug 5, 2026	Aug 5, 2026	SEC EDGAR
Current report	8-K	Jun 10, 2026	Jun 10, 2026	SEC EDGAR
Current report	8-K	May 18, 2026	May 19, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 10, 2026	Apr 24, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 26, 2026	SEC EDGAR
Current report	8-K	Feb 26, 2026	Feb 26, 2026	SEC EDGAR
Current report	8-K	Jan 8, 2026	Jan 8, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 6, 2025	SEC EDGAR
Current report	8-K	Aug 6, 2025	Aug 6, 2025	SEC EDGAR
Current report	8-K	Jun 11, 2025	Jun 11, 2025	SEC EDGAR
Current report	8-K	May 30, 2025	Jun 3, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 8, 2025	SEC EDGAR
Current report	8-K	May 8, 2025	May 8, 2025	SEC EDGAR
Current report	8-K	Apr 29, 2025	Apr 29, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 11, 2025	Apr 25, 2025	SEC EDGAR
Current report	8-K	Mar 24, 2025	Mar 24, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Feb 27, 2025	SEC EDGAR
Current report	8-K	Feb 27, 2025	Feb 27, 2025	SEC EDGAR
Current report	8-K	Feb 24, 2025	Feb 24, 2025	SEC EDGAR
Current report	8-K	Feb 3, 2025	Feb 3, 2025	SEC EDGAR
Current report	8-K	Jan 15, 2025	Jan 15, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 5, 2024	SEC EDGAR
Current report	8-K	Nov 5, 2024	Nov 5, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 13, 2024	SEC EDGAR
Current report	8-K	Aug 13, 2024	Aug 13, 2024	SEC EDGAR
Current report	8-K	Jun 24, 2024	Jun 24, 2024	SEC EDGAR
Current report	8-K	Jun 24, 2024	Jun 24, 2024	SEC EDGAR
Current report	8-K	Jun 13, 2024	Jun 13, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 7, 2024	SEC EDGAR
Current report	8-K	May 7, 2024	May 7, 2024	SEC EDGAR
Proxy statement	DEF 14A	Jun 13, 2024	Apr 29, 2024	SEC EDGAR
Annual report	10-K	Dec 31, 2023	Mar 13, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Entrada Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TRDA.

Compare: TRDA vs CAMP · TRDA vs PRAX · TRDA vs XBIO · TRDA vs IRD · TRDA vs COYA

Revenue growth-93.5% · median 10.5%

Operating margin-4303.8% · median -726.5%

Net margin-4058.0% · median -1185.1%

Company	Revenue	Growth
IRD	$7.91M	-45.9%
CAMP	$5.32M	+39.9%
COYA	$4.69M	+17.6%
TRDA	$3.98M	-93.5%
XBIO	$2.96M	+3.5%
PRAX	–	–

Company

Next earnings (est.): Feb 25, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 152
Held by institutions: 75.6%
Auditor: Ernst & Young LLP
SEC CIK: 1689375

Advertisement
300 × 250

See a number that looks wrong?